BioNxt Solutions Inc. (BNXT) | WebDisclosure

Basculer en Français

8295	Companies
114809	Keywords
55260	Articles
62422	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

BRIEF

published on 10/29/2024 at 08:10, 23 days 1 hour ago

BioNxt avance dans ses démarches de dépôt de brevets pour un nouveau mode d'administration de médicaments

Sclérose En Plaques Solutions BioNxt Myasthénie Grave Médicaments Sublinguaux Dépôts De Brevets
BRIEF

published on 10/29/2024 at 08:10, 23 days 1 hour ago

BioNxt Advances Patent Filings for Novel Drug Delivery

Multiple Sclerosis Patent Filings BioNxt Solutions Myasthenia Gravis Sublingual Drugs
PRESS RELEASE

published on 10/29/2024 at 08:05, 23 days 1 hour ago

BioNxt Announces National Level Patent Filings for Sublingual Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
BioNxt Solutions Inc. initiates nationalization process for sublingual anticancer drug patents for autoimmune neurodegenerative diseases. Positive report from European Patent Office on patentability

BioNxt Solutions Inc. Patents Anticancer Drugs Sublingual Delivery Autoimmune Neurodegenerative Diseases
BRIEF

published on 10/07/2024 at 09:10, 1 month 14 days ago

Terry Lynch rejoint BioNxt Solutions en tant que conseiller en marchés financiers

Sclérose En Plaques Marchés Des Capitaux Solutions BioNxt Terry Lynch Cladribine Sublinguale
BRIEF

published on 10/07/2024 at 09:10, 1 month 14 days ago

Terry Lynch Joins BioNxt Solutions as Capital Markets Advisor

Capital Markets Multiple Sclerosis BioNxt Solutions Terry Lynch Sublingual Cladribine
PRESS RELEASE

published on 10/07/2024 at 09:05, 1 month 14 days ago

Terry Lynch Joins BioNxt as Capital Markets Advisor
BioNxt Solutions Inc. appoints Terry Lynch, a capital markets advisor with extensive experience in resource and bioscience sectors. Mr. Lynch joins the team to support the development and commercialization of the sublingual Cladribine product for MS treatment

BioNxt Solutions Inc. Terry Lynch Sublingual Cladribine Capital Markets Advisor MS Treatment
BRIEF

published on 09/26/2024 at 09:10, 1 month 25 days ago

BioNxt Provides Update on Cladribine Program for Multiple Sclerosis

Investor Relations Multiple Sclerosis Cladribine BioNxt Solutions Patent Approval
BRIEF

published on 09/26/2024 at 09:10, 1 month 25 days ago

BioNxt fait le point sur son programme de cladribine pour la sclérose en plaques

Sclérose En Plaques Relations Avec Les Investisseurs Cladribine Solutions BioNxt Approbation Du Brevet
PRESS RELEASE

published on 09/26/2024 at 09:05, 1 month 25 days ago

BioNxt Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent, and Investor Relations Activities
BioNxt Solutions Inc. updates on sublingual Cladribine drug formulation program for Multiple Sclerosis, patent applications, and investor relations activities. Company aims to revolutionize drug delivery systems for CNS diseases

Investor Relations BioNxt Solutions Inc. Multiple Sclerosis Cladribine Patent Application
BRIEF

published on 09/09/2024 at 22:35, 2 months 11 days ago

BioNxt Receives Positive International Examination Report From the European Patent Office

Multiple Sclerosis BioNxt Solutions European Patent Office Sublingual Drug Delivery Myasthenia Gravis

1 2 ... 7

Accesswire

Published on 11/21/2024 at 09:00, 38 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 3 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 13 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 38 minutes ago

Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 38 minutes ago

Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 09:01, 37 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 08:59, 38 minutes ago

Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 38 minutes ago

Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 23 minutes ago

EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.
Published on 11/21/2024 at 08:09, 1 hour 28 minutes ago

KAP HOLDS ITS GROUND IN A DIFFICULT INDUSTRY ENVIRONMENT IN THE FIRST NINE MONTHS OF 2024

Les Echos

Published on 11/21/2024 at 06:58, 2 hours 40 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 40 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 40 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 30 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 18 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE